Till startsida
University of Gothenburg
Sitemap
To content Read more abput how we use cookies on gu.se

TAT Group to test Farletuzumab

News: Oct 14, 2015

We are happy to announce that an MTA has been signed with Morphotek, Exton, PA USA, that will make farletuzumab available for preclinical work-up of its potential to be used as an alphatherapy vector.
Farletuzumab is an optimized anti-folate receptor alpha (FOLR1) mAb generated by Morphotek with their morphogenics technology, it is the humanized version of the murine LK26. The folate receptor alpha is overexpressed in ovarian cancer but almost absent in normal tissues making it a much suitable vector for radioimmunotherapy. Interestingly, this is the same antigen that we where aiming at in the mid-late 1990ies using a different antibody.

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

BY:

Page Manager: Emma Aneheim|Last update: 4/8/2011
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://tat.gu.se/current/news/n//tat-group-to-test-farletuzumab.cid1328489
Utskriftsdatum: 2017-04-29